Introduction
============

Nasopharyngeal carcinoma (NPC) is highly prevalent in eastern Asia, with the highest incidence reported in the southern provinces of China [@B1]. Due to its anatomical location and non-specific symptoms, early diagnosis and treatment of NPC are difficult [@B2], [@B3]. According to the 7th Edition of the American Joint Commission on Cancer Staging System, 60-70% of NPC patients present with locally advanced (stage III-IVB) disease [@B4], which carries a higher risk of loco-regional recurrence and distant metastasis [@B5]. For those relapsed with distant metastasis, the prognosis is poor, with a median survival ranging from 5 to 11 months [@B6]-[@B8].

Numerous randomized clinical trials have demonstrated that concurrent chemo-radiotherapy confers a survival benefit in locally advanced NPC [@B9]-[@B12]. Cisplatin-based concomitant chemo-radiotherapy (CDDP) has been selected as the standard treatment regimen for patients with locally advanced stage NPC [@B13]. The 2013 National Comprehensive Cancer Network (NCCN) guidelines recommend that concurrent cisplatin be delivered at an intermediate dose weekly (40 mg/m^2^) or a high dose (100 mg/m^2^) at three-week intervals for stage III-IVB NPC[@B14](14)(14)(14). Three studies compared these regimens and reported comparable survival outcomes (overall survival and disease-free survival) based on small sample sizes [@B15]-[@B17]. However, the clinical characteristics between the groups were unevenly distributed, and patients treated with 3-dimensional conformal radiotherapy were also included, which might confound the findings.

With these regimens, excellent local control can be realized with recent technical improvements in radiotherapy delivery, such as intensity-modulated radiation therapy (IMRT), and distant metastasis is now the main cause of treatment failure [@B18]. Therefore, the distant metastasis-free survival outcome is the crucial evaluation indicator of treatment efficiency, especially in locally advanced NPC patients.

The present study conducted propensity score analysis to compare the efficacy and acute toxicities between different CDDP treatment schedules (weekly *vs*. triweekly) in a large cohort. Moreover, we selected distant metastasis-free survival (DMFS) and loco-regional relapse-free survival (LRRFS), apart from overall survival (OS) and disease-free survival (DFS), as the evaluation indicators of efficacy. Our results provide evidence for choosing the appropriate CDDP treatment strategy for locally advanced NPC patients and will inform the design of future prospective studies.

Materials and Methods
=====================

Patient selection and study design
----------------------------------

A total of 3,799 patients diagnosed with locally advanced NPC at Sun Yat-Sen University Cancer Center between January 2010 and December 2013 were retrospectively reviewed. Given the long time span, tumour grade and stage were restaged according to the International Union Against Cancer (UICC) Staging System (7th edition, 2011). Prior patient consent and approval from the Sun Yat-sen University Cancer Center Institutional Review Board were obtained for the use of clinical data. The inclusion criteria were defined as follows: (a) histologically proven NPC; (b) clinically diagnosed as stage III-IVb disease; and (c) treated with cisplatin chemotherapy concurrent with IMRT. The exclusion criteria were as follows: (a) concurrent malignant disease; and (b) the use of adjuvant chemotherapy or additional concurrent targeted therapy.

Finally, 926 patients were evaluated in our study after applying the inclusion and exclusion criteria. We further used propensity scores to adjust for age, sex, Karnofsky performance status score (KPS), tumour stage (T classification), node stage (N classification) and clinical stage and then created a well-balanced cohort by matching each patient who underwent weekly cisplatin concurrent chemotherapy with no more than three patients who underwent IMRT plus triweekly cisplatin concurrent chemotherapy. From this stratification process, we selected a total of 859 patients, comprising 225 patients in the weekly CDDP group and 634 patients in the triweekly CDDP group (Table [1](#T1){ref-type="table"}). Then, we conducted case-matched comparisons of the treatment efficacy and safety in this well-balanced large cohort. The flow diagram of this study design is shown in Figure [1](#F1){ref-type="fig"}. Moreover, we conducted multivariate and subgroup analyses of all 3,799 cases. The key raw data of this study has been validated by uploading onto the Research Data Deposit public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)) at Sun Yat-sen University Cancer Center.

Treatment
---------

The radiation technology used in the present study was IMRT. All patients were treated with radiotherapy 5 days per week in once-daily fractions. The details of the prescribed radiation dose used at SYSUCC have been described in previous studies [@B16], [@B19]. Radiotherapy quality assurance (QA) was performed before radiation treatment for all the NPC patients. CDDP was initiated on the first day of radiotherapy, and the choice of cisplatin every three weeks (100 mg/m^2^) on days 1, 22, and 43 during radiotherapy or weekly CDDP (40 mg/ m^2^) was based on the oncologists\' opinions.

Evaluation and follow-up
------------------------

Patients were examined weekly during the course of CDDP. Chemotherapy-related acute toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Radiotherapy-related toxic effects were evaluated based on the Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group. Acute toxicities were defined as those occurring either during the course of IMRT or within 90 days of its completion.

The follow-up period was the duration from the date of entry into the study to the day of death or the day of the last follow-up (10 October, 2017). After treatment, patients were observed at least once every 3 months during the first 3 years and then every 6 months thereafter until death. At every follow-up, we assessed disease status with complete nasopharyngoscopy, magnetic resonance imaging (MRI) of the head and neck, chest radiography, abdominal sonography, whole-body bone scan or positron emission tomography-computed tomography (PET-CT). DFS was defined as the date of pathological diagnosis to the date of the first recurrence/distant metastasis at any site, death from any cause, or the date of last follow-up visit. DMFS was defined as the date of diagnosis to the date of distant metastasis at any site. LRRFS was defined as the date of diagnosis to the date of loco-regional relapse. OS was calculated as the length of time between the date of initial pathological diagnosis and the date of all death events or last follow-up.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 22.0 software. Categorical variables and acute toxicities were compared using the χ^2^ or Fisher\'s exact test. Continuous variables were analysed using the Mann-Whitney *U*-test. The survival curves were constructed using the Kaplan-Meier method and analysed using the log-rank test. Prognostic factors for survival outcome were analysed with univariate and multivariate Cox regression analyses. The results are presented as hazard ratios (HR) and 95% confidence intervals (CI). HR \> 1 indicates an elevated risk relative to the reference variable. An interaction term between the treatment regimen status and the independent prognostic factors was added to test the effect of their interaction. In all analyses, statistical significance was set at a *P* value less than 0.05 (two-tailed).

Results
=======

Patient characteristics and compliance
--------------------------------------

The regimen of triweekly CDDP (699) was more frequently used compared with weekly CDDP (227) in our cancer centre (Figure [1](#F1){ref-type="fig"}). After propensity score matching (PSM), 634 patients were included in the triweekly group and 225 patients in the weekly group. The baseline demographic and clinical characteristics were well balanced between the two groups (Table [1](#T1){ref-type="table"}). All the patients (859) completed IMRT at the recommended dose.

For both groups, the chemotherapy cycles were more than one. All of the patients received 100 mg/m^2^ in the triweekly group and 40 mg/m^2^ cisplatin in the weekly group. The mean cumulative dose of cisplatin was similar between the weekly and triweekly groups (229.2 mg/m^2^*vs.* 228.0 mg/m^2^). In the weekly group, the majority (206/225, 92%) of patients received at least five chemotherapy cycles, including 39/225 (17%) patients with seven cycles of CDDP (IQR 5-6) (Supplementary Figure [1](#SM0){ref-type="supplementary-material"}A). In the triweekly group, 619/634 (97%) patients received at least two cycles of cisplatin chemotherapy, including 192/634 (30%) patients who completed three cycles of concurrent chemotherapy (IQR 2-3) (Supplementary Figure [1](#SM0){ref-type="supplementary-material"}B).

Efficacy
--------

The median follow-up time was 51 months (range, 1 - 68 months) in the weekly group and 50 months (range, 1 - 69 months) in the triweekly group. Patients in the weekly CDDP group (1-, 3- and 5-year DFS rate, 94%, 86% and 82%, respectively) showed favourable DFS survival compared with patients in the triweekly group (1-, 3- and 5-year DFS rate, 89%, 83% and 81%, respectively), but a significant difference between these two groups was not observed (*P* = .326; Figure [2](#F2){ref-type="fig"}A). The risk of distant metastasis was lower among the patients treated with weekly CDDP than among those treated with triweekly CDDP (HR for DMFS, 0.45; 95% CI, 0.21 - 0.94; *P* = .028; Figure [2](#F2){ref-type="fig"}B). Moreover, the 1-, 3- and 5-year rates of DMFS achieved with weekly CDDP (97%, 97%, and 96%, respectively) were higher than those achieved with triweekly CDDP (94%, 92%, and 91%, respectively). However, the LRRFS and OS were not significantly different between the two treatment groups (HR for LRRFS, 1.03; 95% CI, 0.57 - 1.88; *P* = .932; Figure [2](#F2){ref-type="fig"}C; HR for OS, 1.11; 95% CI, 0.65 - 1.90; *P* = .715; Figure [2](#F2){ref-type="fig"}D). The 5-year LRRFS and OS rates were similar at 91% and 89%, respectively, in the weekly group and 92% and 91%, respectively, in the triweekly group.

Safety
------

The grade 3-4 systemic toxicities are displayed in Table [2](#T2){ref-type="table"}. No treatment-related deaths were seen in either group. Of the 859 patients in the propensity score-matched cohort, the most common grade 3-4 haematological adverse event was leukopenia (126/859, 14.7%). The most commonly recorded grade 3-4 nonhaematological adverse event was mucositis (147/859, 17.1%). The weekly group showed significantly higher proportions of grade 3-4 thrombocytopenia than did the triweekly group (odds ratio \[OR\], 6.56; 95% CI, 2.00 - 21.53; *P* = .002) but lower proportions of grade 3-4 mucositis (OR, 0.52; 95% CI, 0.33 - 0.83; *P* = .006), nausea (OR, 0.20; 95% CI, 0.08 - 0.50; *P* = .001) and vomiting (OR, 0.21; 95% CI, 0.08 - 0.54; *P* = .001) than detected in the triweekly group.

Multivariate analysis and subgroup analysis
-------------------------------------------

Univariate and multivariate analyses were conducted in the cohort of all 926 patients. Various prognostic parameters, including age (≤ 45 years *vs*. \> 45 years), sex, KPS status, T classification (T1-2 *vs*. T3 *vs*. T4), N classification (N0-1 *vs*. N2-3), clinical stage and concurrent chemotherapy regimen (weekly CDDP *vs*. triweekly CDDP), were included in the analysis. After adjusting for these parameters, significantly lower risks of distant metastasis (HR 0.43, 95% CI 0.20 - 0.90, *P* = .026) were found among patients treated with weekly CDDP than among patients treated with triweekly CDDP (Supplementary Table [1](#SM0){ref-type="supplementary-material"} and Table [3](#T3){ref-type="table"}). Moreover, advanced N stage was a significant risk factor for DMFS (HR 1.89, 95% CI 1.08 - 3.34, *P* = .027) and OS (HR 1.72, 95% CI 1.00 - 2.93, *P* = .048). We further performed an interaction analysis, which demonstrated no significant interaction effect between treatment regimen (weekly *vs*. triweekly CDDP) and N classification from DFS, DMFS, LRRFS and OS (all *P* \> .05, Table [4](#T4){ref-type="table"}).

Discussion
==========

The present study is the first propensity score analysis to evaluate the efficacy and acute toxicity of these two chemotherapy regimens using a large cohort (926 locally advanced NPC patients). PSM was used to balance the baseline characteristics between the groups, which allowed us to draw reliable conclusions. In both the pre-matched and matched cohorts, patients with locally advanced NPC treated with the weekly CDDP regimen achieved significantly improved DMFS but not DMS, LRRFS or OS.

Previous studies have detected the same insignificant results for DMS and OS when directly comparing the above concurrent chemotherapy regimens [@B15]-[@B17]. Considering the majority of treatment failures are due to distant metastasis, especially in patients with locally advanced stage disease [@B20], [@B21], our study used DMFS as the end point and detected a positive association with a weekly CDDP treatment schedule.

In the past decade, the potential benefit of using comparatively low doses of chemotherapy drugs on a more frequent schedule has gradually been appreciated [@B22]. Initially, it was reported that this type of regimen exerts effects exclusively by preventing angiogenesis [@B23]. Recent evidence revealed an additional mechanism, that the same overall dose administered as a low-dose regimen prevented carcinoma cell phenotypic conversion into stem-like tumour-initiating cells, thus enhancing treatment response and extending survival [@B24]. Intriguingly, the improvement in DMFS did not translate into an improvement in OS in the current study, which may be due to the 25% (14/56) of patients who developed distant metastasis and were still alive at the date of last follow-up. Therefore, further follow-up is needed to fully evaluate long-term survival.

Compared with conventional radiotherapy, IMRT has the advantage of improving target coverage and applying a more accurate dose to the tumour target while sparing normal organs [@B25]-[@B27]. Due to recent advances in the radiation techniques of IMRT, a 90% local control rate for NPC treated with IMRT plus chemotherapy has been reported, even for patients with locally advanced disease [@B28]. In our study, the 5-year LRRFS was 91% in the weekly group and 92% in the triweekly group. The above favourable results of LRRFS in both groups might have narrowed any potential therapeutic gain of concurrent chemotherapy for local control.

The cumulative dose intensity of cisplatin has been reported to be an important prognostic factor in NPC patients treated with CCRT regimens [@B29]. However, the mean cumulative cisplatin dose (weekly *vs.* triweekly, 229.2 mg/m^2^ *vs.* 228.0 mg/m^2^) was similar between groups in our study. Although lower compliance rates of concurrent cisplatin chemotherapy were detected when compared with previous trials [@B15], [@B17], it should be noted that the majority of patients received at least five cycles of CDDP in the weekly group (92%) and two cycles of CDDP in the triweekly group (97%). In our cancer centre, weekly cisplatin at a dose of 40 mg/m^2^ is mainly delivered to outpatients, while 100 mg/m^2^ cisplatin triweekly concurrently with IMRT regimen is mostly administered to hospitalized patients [@B16]. Poor compliance by outpatients and insufficient hospital beds often lead to the postponement of concurrent chemotherapy and patients skipping the final cycle of chemotherapy.

The concept of lower-dose cisplatin, given on a weekly basis concurrent with radiotherapy, is based on the hypothesis that an intermediate cisplatin dose with frequently administered will decrease the toxicity profile while maintaining efficacy. A previous randomized phase III trial confirmed that weekly cisplatin concurrent with radiotherapy conferred a survival benefit compared with radiotherapy alone [@B12]. However, the difference in the toxicity profile between the two concurrent chemotherapy schedules is controversial. Ho et al. found that the incidence of grade 3-4 toxic events of any type was not decreased in locally advanced patients treated with the weekly regimen[@B30]. Conversely, Tao et al. demonstrated a slightly lower incidence of grade 3-4 dysphagia and gastrointestinal reactions with a weekly regimen (dysphagia, 4.1%; gastrointestinal reactions, 0.0%; respectively) than with a triweekly regimen (dysphagia, 6.2%; gastrointestinal reactions, 3.7%; respectively), but this difference was not significant [@B16]. Based on a large cohort, our study found a significant difference in severe toxicity with a higher incidence of thrombocytopenia, whereas there was a lower incidence of grade 3-4 gastrointestinal reactions (nausea and vomiting) and mucositis with the weekly CDDP regimen. Hence, clinicians should adopt aggressive action such as adequate monitoring of blood counts and oral care to avoid any severe toxicity depending on the choice of concurrent chemotherapy treatment regimen.

Our study has several limitations. Although PSM analysis was conducted to minimize the impact of observed confounders [@B31], [@B32], it is unclear whether other confounding factors still exist. Quantification of plasma Epstein-Barr virus (EBV) DNA has been demonstrated to be useful for predicting the survival outcome in advanced NPC patients [@B33]. However, the EBV DNA load was not included in our study because standardization of the assay remained unresolved before the patients enrolled in the study. Moreover, the present study was a single-centre retrospective study, and further multi-centre prospective randomized studies are needed.

Conclusions
===========

IMRT concurrent with a weekly cisplatin regimen significantly improved DMFS but not DMS, LRRFS or OS than triweekly cisplatin regimen in patients with locally advanced NPC. Differences in the selected acute toxicities were also observed between the two groups. This study will provide evidence for clinicians to choose the appropriate strategy for locally advanced NPC patients and inform the design of future prospective studies.
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![**CONSORT flow diagram.** Abbreviations: NPC: nasopharyngeal carcinoma; IMRT: intensity-modulated radiotherapy.](jcav09p3447g001){#F1}

![**Comparison of survival according to weekly and triweekly concurrent cisplatin chemotherapy plus intensity-modulated radiotherapy regimen in the well-balanced cohort. (A)** Disease-free survival. **(B)** Distant metastasis-free survival. **(C)** Loco-regional recurrence-free survival and **(D)** Overall survival. The hazard ratio (HR) was calculated with the Cox proportional-hazards model; *P* values were calculated with the log-rank test.](jcav09p3447g002){#F2}

###### 

Baseline characteristics of the unmatched and matched groups

  Characteristics    Before Matching (N=926)                  After Matching (N=859)                                               
  ------------------ ------------------------- -------------- ------------------------ ------------- -------------- -------------- --------------
  Age, years         45.1 (15-72)              45.3 (18-74)   0.838**^&^**                           45.2 (15-72)   45.0 (18-74)   0.830**^&^**
  Sex                                                                                                                              
  Male               171 (75.3%)               519 (25.8%)    0.745                                  170 (75.6%)    475 (74.9%)    0.850
  Female             56 (24.7%)                180 (74.2%)                             55 (24.4%)    159 (25.1%)                   
  KPS                                                                                                                              
  90-100             222 (97.8%)               690 (98.7%)    0.349                                  222 (98.7%)    630 (99.4%)    0.386
  70-80              5 (2.2%)                  9 (1.3%)                                3 (1.3%)      4 (0.6%)                      
  T classification                                                                                                                 
  T1                 7 (3.1%)                  15 (2.1%)      0.336                                  7 (3.1%)       15 (2.3%)      0.802
  T2                 27 (11.9%)                72 (10.3%)                              26 (11.6%)    62 (9.8%)                     
  T3                 163 (71.8%)               487 (69. 7%)                            162 (72.0%)   469 (74.0%)                   
  T4                 30 (13.2%)                125 (17.9%)                             30 (13.3%)    88 (13.9%)                    
  N classification                                                                                                                 
  N0                 22 (9.7%)                 68 (9.7%)      0.320                                  22 (9.8%)      61 (9.6%)      0.494
  N1                 103 (45.4%)               342 (48.9%)                             103 (45.8%)   320 (40.5%)                   
  N2                 91 (40.1%)                239 (34.2%)                             90 (40.0%)    219 (34.5%)                   
  N3                 11 (4.8%)                 50 (7.2%)                               10 (4.4%)     34 (5.4%)                     
  Clinical stage                                                                                                                   
  III                188 (82.8%)               533 (76.3%)    0.038                                  187 (82.7%)    519 (81.9%)    0.674
  IV                 39 (17.2%)                166 (23.7%)                             38 (17.3%)    115 (18.1%)                   

Data represent the median (range) and n (%), unless otherwise indicated. ^¶^ χ^2^ test or Fisher\'s exact test. ^&^ Mann-Whitney U-test.

Abbreviations: KPS, Karnofsky performance score.

###### 

Acute adverse events in the propensity score-matched cohort of NPC patients

  Event                Triweekly (N=634)   Weekly (N=225)   OR (95% CI)         *P*
  -------------------- ------------------- ---------------- ------------------- -----------
  Haematological                                                                
  Anaemia              6 (0.9)             4 (1.8)                              0.326
  Thrombocytopenia     4 (0.6)             9 (4.0)          6.56 (2.00-21.53)   **0.002**
  Neutropenia          36 (5.7)            18 (8.0)                             0.220
  Leukopenia           88 (13.9)           38 (16.8)                            0.274
  Non-haematological                                                            
  Nephrotoxicity       0 (0.0)             0 (0.0)                              ---
  Hepatoxicity         5 (0.8)             2 (0.9)                              0.886
  Nausea               65 (10.3)           5 (2.2)          0.20 (0.08-0.50)    **0.001**
  Vomiting             61 (9.6)            5 (2.2)          0.21 (0.08-0.54)    **0.001**
  Diarrhea             0 (0.0)             0 (0.0)                              ---
  Skin reaction        12 (1.9)            6 (2.7)                              0.488
  Mucositis            122 (19.2)          25 (11.1)        0.52 (0.33-0.83)    **0.006**
  Weight loss          6 (0.9)             2 (0.9)                              0.939

Data represent the number of patients with events (%). P values were calculated with the χ² test.

###### 

Multivariate analysis in the unmatched group

  Variable              Disease-free survival               Distant metastasis-free survival      Loco-regional relapse-free survival               Overall survival                                                         
  ------------------ -- ----------------------- ----------- ---------------------------------- -- ------------------------------------- ----------- ------------------ -- ------ ------------ ------- -- ------- ----------- -----------
  Sex                                                                                                                                                                                                                        
  Female                Ref.                    Ref.                                              Ref.                                  Ref.                              Ref.   Ref.                    Ref.    Ref.        
  Male                  1.08                    0.71-1.64   0.712                                 1.63                                  0.83-3.22   0.159                 1.84   0.90-3.76    0.094      0.98    0.56-1.69   0.932
  Age                                                                                                                                                                                                                        
  ≤45                   Ref.                    Ref.                                              Ref.                                  Ref.                              Ref.   Ref.                    Ref.    Ref.        
  \>45                  1.02                    0.72-1.45   0.908                                 0.74                                  0.44-1.24   0.255                 1.42   0.84-2.38    0.188      2.29    1.40-3.73   **0.001**
  KPS                                                                                                                                                                                                                        
  70-80                 Ref.                    Ref.                                              Ref.                                  Ref.                              Ref.   Ref.                    Ref.    Ref.        
  90-100                0.38                    0.14-1.05   0.061                                 0.25                                  0.08-0.83   **0.023**             0.63   0.09-4.62    0.650      0.34    0.10-1.11   0.074
  T classification                                                                                                                                                                                                           
  T1-2                  Ref.                    Ref.                                              Ref.                                  Ref.                              Ref.   Ref.                    Ref.    Ref.        
  T3                    1.12.                   0.62-2.02   0.711                                 0.96                                  0.45-2.06   0.915                 1.33   0.55-3.18    0.529      0.96.   0.47-1.93   0.903
  T4                    1.53                    0.60-3.92   0.372                                 1.36                                  0.47-3.95   0.572                 4.78   0.64-35.53   0.126      1.31    0.44-3.89   0.625
  N classification                                                                                                                                                                                                           
  N0-1                  Ref.                    Ref.                                              Ref.                                  Ref.                              Ref.   Ref.                    Ref.    Ref.        
  N2-3                  1.30                    0.87-1.94   0.202                                 1.89                                  1.08-3.34   **0.027**             1.52   0.86-2.69    0.151      1.72    1.00-2.93   **0.048**
  Clinical stage                                                                                                                                                                                                             
  III                   Ref.                    Ref.                                              Ref.                                  Ref.                              Ref.   Ref.                    Ref.    Ref.        
  IV                    1.18                    0.56-2.52   0.663                                 1.90                                  0.80-4.49   0.145                 0.32   0.05-1.92    0.211      1.71    0.73-4.01   0.216
  Treatment                                                                                                                                                                                                                  
  Triweekly             Ref.                    Ref.                                              Ref.                                  Ref.                              Ref.   Ref.                    Ref.    Ref.        
  Weekly                0.67                    0.43-1.06   0.084                                 0.43                                  0.20-0.90   **0.026**             0.94   0.52-1.70    0.836      1.10    0.64-1.86   0.737

###### 

Interaction between treatment and other significant prognostic factors and its effect on disease-free survival, distant metastasis-free survival, loco-regional relapse-free survival, and overall survival

                                                      DFS                        DMFS                       LRRFS      OS                                                
  --------------------------------------------------- ------------------ ------- ------ ------------------- ------- -- ------------------ ------- -- ------------------- -------
  **Treatment regimen status and Age**                                                                                                                                   
  ***Treatment***                                                                                                                                                        
  Triweekly                                           Ref.                              Ref.                           Ref.                          Ref.                
  Weekly                                              1.09 (0.44-2.68)   0.852          0.62 (0.27-1.43)    0.262      0.88 (0.37-2.01)   0.774      0.49 (0.17-1.44)    0.192
  ***Age***                                                                                                                                                              
  ≤45                                                 Ref.                              Ref.                           Ref.                          Ref.                
  \>45                                                1.00 (0.68-1.49)   0.984          0.86 (0.50-1.49)    0.586      1.37 (0.75-2.50)   0.303      1.72 (0.98-3.00)    0.057
  ***Interaction effect***                                                                                                                                               
  Weekly \* \>45                                      1.09 (0.44-2.68)   0.852          0.22 (0.03-1.94)    0.174      1.13 (0.35-3.70)   0.839      3.25 (0.93-11.32)   0.065
  **Treatment regimen status and N classification**                                                                                                                      
  ***Treatment***                                                                                                                                                        
  Triweekly                                           Ref.                              Ref.                           Ref.                          Ref.                
  Weekly                                              0.64 (0.34-1.20)   0.160          0.24 (0.06-1.03)    0.056      1.04 (0.47-2.34)   0.916      0.84 (0.36-1.93)    0.677
  ***N classification***                                                                                                                                                 
  N0-1                                                Ref.                              Ref.                           Ref.                          Ref.                
  N2-3                                                1.27 (0.82-1.97)   0.283          1.71 (0.94-3.11)    0.077      1.61 (0.84-3.06)   0.149      1.51 (0.82-2.77)    0.180
  ***Interaction effect***                                                                                                                                               
  Weekly \* N2-3                                      1.12 (0.46-2.73)   0.808          2.33 (0.43-12.67)   0.326      0.80 (0.25-2.61)   0.713      1.61 (0.55-4.76)    0.389
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